Successor for Chairman

Successor for Chairman

03.04.2013 - Swiss Basilea Ltd has proposed Martin Nicklasson as the successor to Chairman Werner Henrich, whose term will end in June.

Dr Nicklasson is a high-profile pharmaceutical business professional with longstanding operational and board experience. Born in 1955, the Swedish pharmacist is Associate Professor at the Department of Pharmaceutics, University of Uppsala. Dr Nicklasson has held numerous leadership and executive positions in commercial operations and drug development at AstraZeneca Plc. He was the President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB and serves as a Board Member in a number of biotech companies in Europe and the US.

31.07.2013 British Abcam plc (Cambridge) has named Alan Hirzel as Chief Marketing Officer in an attempt to boost future growth in the protein research tool market. Alan will take responsibility for Abcam’s branding, product portfolio and online consumer offering.

He has more than 20 years of global business and leadership experience. Prior to joining Abcam, he spent 14 years with Bain & Company, served at The Social Business Trust, and has recently been appointed to the board of the UK National Citizen Service.

23.07.2013 The BioIndustry Association (BIA) board has elected Edward Hodgkin as its new Chairman, effective as of 30 October 2013. He succeeds Tim Edwards, who will remain a member of the BIA Board.

Hodgkin is a pharmaceutical/biotech executive with 22 years of experience in Big Pharma, research services and start-up bio-tech ventures. He has been the BIA's Non-executive Director since 2010. The chemist is a partner at Syncona Partners, where he leads new life science ventures. Prior to joining Syncona in April 2013, he was CEO of Biotica Technology Ltd. 

09.07.2013 Orexo AB has named Henrik Juuel as new Executive Vice President and CFO. According to the company, Juuel brings in extensive experience from senior managements positions within the life science industry, including positions as CFO for NNE Pharmaplan and GN Resound.

“His experience from financial management of international commercial operations will be important for the success of Orexo AB, as our company continues expanding,” says Nikolaj Sørensen, President and CEO of Orexo. Henrik Juuel succeeds Carl-Johan Blomberg, who will leave Orexo after successful two-year tenure.

02.07.2013 Rob Duchateau, private lecturer at the University of Eindhoven (Netherlands) and academic head of SABICO, has received this year’s DPI Award.

At the end of June, the Dutch Polymer Institute Invention Award has been handed at the biennial conference of the European Polymer Federation (EPF) in Pisa, Italy. The Jury underlined Duchateau’s merits in the field of polymer applications and properties as an outstanding example for connection of academic knowledge with industrial application. In order to promote the significance of inventions, the DPI Invention Award is presented every two years to a scientist from the DPI network. The number of inventions and the industrial relevance are the most important criteria for granting. 

28.06.2013 Swedish biochemist Pål Nyrén has been awarded the European Patent Office’s (EPO) “Inventor of the Year“ for his development of the DNA pyrosequencing technique used in Roche’s and Qiagen’s next generation sequencing machines.

Nyrén is one of five winners of the 2013 European Inventor Award, from a group of 15 total nominees from 11 countries. The winners were announced in the presence of Princess Beatrix of the Netherlands and 500 invited guests from all over the world, including scientists, intellectual property experts, business leaders and political representatives. Nyrén is currently professor in Biochemistry at KTH in Stockholm. He founded Biotage in 1997, the former Pyrosequencing AB.

26.06.2013 Ute Kilger, a partner with Boehmert & Boehmert in Berlin, Germany, was honored for her expertise in Biotechnology Law by Best Lawyers on June 11.

 She works heavily in European patents and trademarks . The attorneys named to Best Lawyers have been recognized by their peers in the legal industry for their professional excellence in their practice areas. Kilger studied chemistry at the University of Merseburg, and completed her doctorate in biochemistry at the Freie Universität Berlin. Following her doctorate, she embarked on her training as a European patent attorney in the patent department of Boehringer Mannheim GmbH. Since August 2009, she has worked as a partner in the areas of biology/chemistry/pharmaceuticals at the Berlin office of Boehmert & Boehmert. She frequently lectures on IP protection at the University of Potsdam and at the Charite-Universitätsmedizin Berlin. 

09.07.2013 Protuduese API specialist Hovione has appointed Justin Hughey to lead the Particle Design sciences at its site in New Jersey.

The pharmacist is an acknowledged expert in the field of solubilization including the creation of amorphous solid dispersions with emphasis on Hot Melt Extrusion.  Hughey comes in from Austin-based cpmpany Enavail where he was Director of Research. His pharmaceutical development experience extends to particle engineering technologies for pulmonary delivery as well as controlled and immediate release solid oral dosage forms. 

09.07.2013 Nicholas Michael has joined British RSSL as Senior Scientist to head up the company's protein characterisation services.

With 10 years' experience in mass spectrometry and HPLC, Nicholas has previously worked at Cancer Research and Lonza Biologics. Protein characterisation, including glycosylation profiling and impurity profiling, is one of several GMP services that RSSL offers to the pharmaceutical/bio-pharma industry.

03.06.2013 Bayer AG’s anti-infectives spin-out AiCuris GmbH and license partner Merck & Co. have been awarded the Allicense 2013 "Breakthrough Alliance Award” for their US$574m agreement in October 2012.

In the running were the five most valuable licensing agreements worldwide as nominated by analysts from Deloitte Recap. An online vote decided the winner. AiCuris CEO Prof. Dr. Helga Rübsamen-Schaeff was given the award at the end of April at the Allicense conference in San Francisco.

07.06.2013 US small molecule-drug conjugates specialist Endocyte has appointed Torsten Hoof as VP and General Manager of the company’s new European headquarters in Zug.

Hoof has extensive knowledge of product launches in the European market. The biochemist comes in from Bristol-Myers Squibb, where most recently he was VP for Global Commercialisation of the hema-tology and oncology franchise. Prior to joining BMS, he was Global Business Leader Influenza at Roche, where he led the worldwide launch of Tamiflu and several launches of HIV products in Germany.

Vorherige Seite4/8Nächste Seite


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • MORPHOSYS64.50 EUR6.19%
  • CO.DON3.10 EUR4.38%
  • 4SC1.23 EUR4.24%


  • THERAMETRICS0.07 CHF-12.50%
  • CYTOS1.24 CHF-3.12%
  • SANTHERA97.60 CHF-2.16%


  • 4SC1.23 EUR78.3%
  • MEDIGENE13.14 EUR67.0%
  • FORMYCON31.20 EUR31.9%


  • THERAMETRICS0.07 CHF-12.5%
  • EPIGENOMICS5.32 EUR-10.4%
  • BB BIOTECH290.10 EUR-8.4%


  • SANTHERA97.60 CHF2649.3%
  • CYTOS1.24 CHF629.4%
  • FORMYCON31.20 EUR339.4%


  • MOLOGEN5.11 EUR-52.7%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.58 EUR-20.9%

No liability assumed, Date: 20.04.2015

Current issue

All issues